Physician profile
Paul W Davis
NPI 1386637221
$4,424.04
in general payments reported to CMS, 2019-2025
39 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $882 · 2021: $1,097 · 2022: $580 · 2023: $823 · 2024: $317 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,538.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $782.35 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $498.23 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $409.72 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $244.15 | 2021-2024 | |
| Novo Nordisk INC | $220.43 | 2020-2025 | |
| Pfizer INC. | $219.75 | 2019-2023 | |
| Allergan, INC. | $219.28 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $192.14 | 2020-2023 | Breztri |
| Novartis Pharmaceuticals Corporation | $186.23 | 2019-2023 | |
| Lilly USA, LLC | $179.96 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.78 | 2025 | Caplyta |
| Amgen INC. | $101.32 | 2019-2025 | Otezla, Repatha, Repatha |
| Teva Pharmaceuticals USA, INC. | $82.68 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $72.52 | 2020 | |
| Supernus Pharmaceuticals, INC. | $71.50 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.